Commercial Launch of AKTOCYTE: A Transformative Step in Cancer Care
Commercial Launch of AKTOCYTE: A Transformative Step in Cancer Care - Press Release
In an encouraging development, #ACKTOCYTE, the groundbreaking nutraceutical developed by the scientists from BARC, ACTREC, and TMH of DAE in collaboration with M/s. IDRS Labs Pvt. Ltd. Bengaluru, has been launched today at the DAE Secretariat in Mumbai. Offering versatile applications, AKTOCYTE serves as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant and is aimed at improving the quality of life for cancer patients. It has received approval from #FSSAI underscoring its safety and adherence to quality standards. Speaking on the occasion, Shri Vivek Bhasin, Director, BARC, appreciated the efforts of DAE scientists and M/s. IDRS for the successful commercialization. Dr. Ajit Kumar Mohanty, Secretary, DAE & Chairman, AEC, conveyed his wishes to the teams of experts for this remarkable achievement. The commercial launch of AKTOCYTE exemplifies successful collaboration with industry and underscores DAE's commitment to pioneering advanced and affordable cancer care solutions.
